Literature DB >> 28570548

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.

Bradley Endres1, Eugénie Bassères1, Tasnuva Rashid1, Long Chang2, M Jahangir Alam1, Kevin W Garey3.   

Abstract

Assessment of antibiotic action with new drug development directed towards anaerobic bacteria is difficult and technically demanding. To gain insight into possible MOA, morphologic changes associated with antibiotic exposure can be visualized using scanning electron microscopy (SEM). Integrating SEM imaging with traditional kill curves may improve our insight into drug action and advance the drug development process. To test this premise, kill curves and SEM studies were conducted using drugs with known but different MOA (vancomycin and metronidazole). C. difficile cells (R20291) were grown with or without the presence of antibiotic for up to 48 h. Throughout the 48 h interval, cells were collected at multiple time points to determine antibiotic efficacy and for imaging on the SEM. Consistent with previous reports, vancomycin and metronidazole had significant bactericidal activity following 24 h of treatment as measured by colony-forming unit (CFU) counting. Using SEM imaging we determined that metronidazole had significant effects on cell length (> 50% reduction in cell length for each antibiotic; P< 0.05) compared to controls and vancomycin. While the phenotypic response to drug treatment has not been documented previously in this manner, they are consistent with the drug's MOA demonstrating the versatility and reliability of the imaging and measurements and the application of this technique for other experimental compounds.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28570548      PMCID: PMC5608145          DOI: 10.3791/55383

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  13 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  New EMA guideline for antimicrobial development.

Authors:  Paul G Ambrose; Sujata M Bhavnani; Michael N Dudley; Evelyn Ellis-Grosse; Christopher M Rubino; George L Drusano
Journal:  Lancet Infect Dis       Date:  2012-04       Impact factor: 25.071

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Investigation of potentially pathogenic Clostridium difficile contamination in household environs.

Authors:  M Jahangir Alam; Ananna Anu; Seth T Walk; Kevin W Garey
Journal:  Anaerobe       Date:  2014-03-19       Impact factor: 3.331

5.  A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.

Authors:  Bradley T Endres; Eugénie Bassères; Ali Memariani; Long Chang; M Jahangir Alam; Richard J Vickers; Ioannis A Kakadiaris; Kevin W Garey
Journal:  Anaerobe       Date:  2016-04-21       Impact factor: 3.331

6.  In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent.

Authors:  Samuel L Aitken; M Jahangir Alam; Mohammed Khaleduzzaman; Mohammed Khaleduzzuman; Seth T Walk; William L Musick; Vy P Pham; Jennifer L Christensen; Robert L Atmar; Yang Xie; Kevin W Garey
Journal:  Infect Control Hosp Epidemiol       Date:  2015-08-20       Impact factor: 3.254

7.  Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.

Authors:  Bradley T Endres; Eugénie Bassères; Mohammed Khaleduzzaman; M Jahangir Alam; Laurent Chesnel; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 8.  Ridinilazole: a novel therapy for Clostridium difficile infection.

Authors:  Richard J Vickers; Glenn Tillotson; Ellie J C Goldstein; Diane M Citron; Kevin W Garey; Mark H Wilcox
Journal:  Int J Antimicrob Agents       Date:  2016-05-30       Impact factor: 5.283

9.  Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.

Authors:  Eugénie Bassères; Bradley T Endres; Mohammed Khaleduzzaman; Faranak Miraftabi; M Jahangir Alam; Richard J Vickers; Kevin W Garey
Journal:  J Antimicrob Chemother       Date:  2016-02-18       Impact factor: 5.790

Review 10.  Clostridium difficile infection: a review of current and emerging therapies.

Authors:  Andrew Ofosu
Journal:  Ann Gastroenterol       Date:  2016 Apr-Jun
View more
  1 in total

1.  Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut-Brain Axis.

Authors:  Melinda A Engevik; Berkley Luck; Chonnikant Visuthranukul; Faith D Ihekweazu; Amy C Engevik; Zhongcheng Shi; Heather A Danhof; Alexandra L Chang-Graham; Anne Hall; Bradley T Endres; Sigmund J Haidacher; Thomas D Horvath; Anthony M Haag; Sridevi Devaraj; Kevin W Garey; Robert A Britton; Joseph M Hyser; Noah F Shroyer; James Versalovic
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.